Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine [3] 13, 58, 65
2 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
3 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
4 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
5 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
6 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
7 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
8 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate [1] 46
9 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
10 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
11 ADORA1 [6] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
12 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine [3] 13, 58, 65
13 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate [1] 46
14 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson [1] 46
15 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
16 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
17 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
18 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
19 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
20 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
21 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
22 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
23 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
24 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
25 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
26 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
27 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
28 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
29 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
30 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
31 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
32 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
33 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
34 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
35 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
36 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
37 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
38 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
39 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
40 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
41 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
42 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
43 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
44 ADRA1D [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
45 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
46 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
47 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
48 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
49 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
50 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
51 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
52 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
53 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
54 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
55 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
56 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
57 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
58 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
59 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
60 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
61 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
62 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
63 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
64 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
65 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
66 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
67 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
68 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
69 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
70 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
71 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
72 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
73 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
74 ADRA1B [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
75 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
76 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
77 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
78 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
79 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
80 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
81 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
82 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
83 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
84 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
85 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
86 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
87 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
88 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
89 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin [1] 13
90 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
91 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
92 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
93 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
94 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
95 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
96 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
97 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
98 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
99 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
100 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin [1] 13
101 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
102 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
103 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
104 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
105 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
106 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
107 ADRA1A [4] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
108 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
109 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
110 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
111 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
112 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
113 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
114 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
115 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
116 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
117 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00560 Pimozide [1] 2
118 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
119 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00606 Guanfacine [1] 193
120 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
121 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
122 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
123 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
124 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
125 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
126 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
127 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
128 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
129 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
130 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
131 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
132 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
133 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
134 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
135 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
136 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
137 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
138 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
139 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08031 Guanfacine [1] 193
140 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
141 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
142 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
143 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
144 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
145 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
146 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
147 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
148 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
149 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
150 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
151 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
152 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
153 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
154 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
155 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
156 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
157 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
158 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
159 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
160 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
161 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
162 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
163 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
164 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
165 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
166 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
167 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
168 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
169 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
170 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
171 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
172 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
173 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
174 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
175 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
176 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
177 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
178 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
179 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
180 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
181 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
182 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
183 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
184 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
185 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
186 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
187 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
188 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
189 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
190 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
191 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
192 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
193 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
194 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
195 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
196 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
197 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
198 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
199 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
200 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
201 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
202 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
203 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
204 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
205 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
206 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
207 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
208 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
209 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
210 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
211 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
212 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
213 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
214 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
215 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
216 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine [1] 22
217 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine [3] 46, 70, 96
218 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00124 Ephedrine [1] 11
219 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00235 Atenolol [1] 167
220 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol [5] 6, 57, 86, 113, 210
221 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00378 Timolol [2] 157, 227
222 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol [1] 6
223 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
224 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00485 Pseudoephedrine [1] 17
225 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00601 Metoprolol [6] 17, 57, 58, 113, 193, 226
226 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00603 Timolol [2] 157, 227
227 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00632 Dobutamine [3] 57, 58, 215
228 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00634 Bisoprolol [3] 67, 86, 113
229 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00636 Amiodarone [2] 28, 127
230 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00644 Esmolol [1] 58
231 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine [3] 46, 70, 96
232 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
233 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine [3] 46, 70, 96
234 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02342 Bisoprolol [3] 67, 86, 113
235 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin [1] 6
236 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol [6] 17, 57, 58, 113, 193, 226
237 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02910 Amiodarone [2] 28, 127
238 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03415 Carvedilol [5] 6, 57, 86, 113, 210
239 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine [3] 57, 58, 215
240 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03880 Dobutamine [3] 57, 58, 215
241 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03881 Dobutamine [3] 57, 58, 215
242 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05011 Metoprolol [6] 17, 57, 58, 113, 193, 226
243 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol [4] 17, 85, 113, 167
244 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05206 Norepinephrine [1] 22
245 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05648 Pseudoephedrine [1] 17
246 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05649 Pseudoephedrine [1] 17
247 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07660 Celiprolol [1] 168
248 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07916 Esmolol [1] 58
249 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
250 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine [1] 17
251 ADRB1 [8] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08600 Timolol [2] 157, 227
252 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
253 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
254 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
255 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol [5] 6, 57, 86, 113, 210
256 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00378 Timolol [2] 157, 227
257 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol [1] 6
258 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
259 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
260 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00603 Timolol [2] 157, 227
261 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00687 Salmeterol [1] 299
262 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00688 Terbutaline [1] 118
263 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
264 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
265 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01373 Formoterol [3] 85, 228, 299
266 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol [14] 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
267 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
268 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol [1] 6
269 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
270 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D03415 Carvedilol [5] 6, 57, 86, 113, 210
271 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
272 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05277 Formoterol [3] 85, 228, 299
273 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
274 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
275 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05792 Salmeterol [1] 299
276 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
277 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07990 Formoterol [3] 85, 228, 299
278 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine [1] 13
279 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08124 Levosalbutamol [1] 49
280 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
281 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
282 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08570 Terbutaline [1] 118
283 ADRB2 [6] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08600 Timolol [2] 157, 227
284 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
285 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
286 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
287 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
288 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
289 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
290 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
291 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
292 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
293 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
294 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
295 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
296 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
297 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
298 ADRB3 [7] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron [4] 6, 13, 53, 226
299 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
300 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
301 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00400 Valsartan [7] 57, 58, 66, 75, 218, 222, 224
302 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan cilexetil [1] 67
303 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan [2] 58, 67
304 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00523 Irbesartan [4] 66, 167, 168, 222
305 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00626 Candesartan cilexetil [1] 67
306 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00627 Telmisartan [2] 66, 67
307 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
308 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
309 AGTR1 [11] cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D11776 Sparsentan [3] 66, 218, 222
310 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
311 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan [7] 51, 84, 85, 86, 88, 210, 211
312 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07171 Sitaxentan [1] 86
313 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
314 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07741 Zibotentan [1] 51
315 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
316 EDNRA [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
317 EDNRB [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
318 EDNRB [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
319 EDNRB [5] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
320 GUCY1A2 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite [1] 58
321 GUCY1A2 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
322 GUCY1A1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite [1] 58
323 GUCY1A1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
324 GUCY1B1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite [1] 58
325 GUCY1B1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
326 INSR [18] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D00085 Insulin human [2] 96, 156
327 INSR [18] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D03230 Insulin human [2] 96, 156
328 INSR [18] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D03250 Insulin glargine [1] 299
329 INSR [18] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D04539 Insulin detemir [1] 299
330 KCNJ8 [1] cGMP-PKG signaling pathway D00636 Amiodarone [2] 28, 127
331 KCNJ8 [1] cGMP-PKG signaling pathway D02910 Amiodarone [2] 28, 127
332 MYH7 [5] cGMP-PKG signaling pathway, Thyroid hormone signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis D12265 Mavacamten [1] 58
333 ATP1A1 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin [1] 299
334 ATP1A1 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin [3] 8, 46, 210
335 ATP1A2 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin [1] 299
336 ATP1A2 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin [3] 8, 46, 210
337 ATP1A3 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin [1] 299
338 ATP1A3 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin [3] 8, 46, 210
339 ATP1A4 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin [1] 299
340 ATP1A4 [11] cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin [3] 8, 46, 210
341 NPR1 [8] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion D04051 Erythrityl tetranitrate [1] 46
342 NPR1 [8] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion D05147 Nesiritide [2] 46, 58
343 NPR2 [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D04051 Erythrityl tetranitrate [1] 46
344 NPR2 [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D11190 Vosoritide [1] 276
345 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00729 Loperamide [2] 13, 97
346 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00843 Nalbuphine [1] 85
347 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
348 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
349 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
350 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
351 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
352 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
353 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
354 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D07113 Loperamide [2] 13, 97
355 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
356 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
357 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
358 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00227 Aminophylline [1] 63
359 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00371 Theophylline [2] 236, 299
360 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
361 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00718 Flavoxate [1] 226
362 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
363 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D01712 Theophylline [2] 236, 299
364 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D02017 Theophylline [2] 236, 299
365 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D05429 Aminophylline [1] 63
366 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D06103 Theophylline [2] 236, 299
367 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D06104 Theophylline [2] 236, 299
368 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D07546 Bucladesine [1] 246
369 PDE2A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D07961 Flavoxate [1] 226
370 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
371 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
372 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00417 Milrinone [1] 294
373 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
374 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00718 Flavoxate [1] 226
375 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01385 Ibudilast [2] 2, 13
376 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
377 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
378 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01896 Cilostazol [3] 51, 70, 124
379 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
380 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D02085 Milrinone [1] 294
381 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D04720 Levosimendan [1] 2
382 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
383 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
384 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
385 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D07546 Bucladesine [1] 246
386 PDE3A [5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D07961 Flavoxate [1] 226
387 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
388 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
389 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00417 Milrinone [1] 294
390 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
391 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00718 Flavoxate [1] 226
392 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01385 Ibudilast [2] 2, 13
393 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
394 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
395 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01896 Cilostazol [3] 51, 70, 124
396 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
397 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02085 Milrinone [1] 294
398 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D04720 Levosimendan [1] 2
399 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
400 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
401 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
402 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D07546 Bucladesine [1] 246
403 PDE3B [9] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D07961 Flavoxate [1] 226
404 PPP3CA [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
405 PPP3CA [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
406 PPP3CA [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
407 PPP3CA [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
408 PPP3CA [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
409 PPP3CB [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
410 PPP3CB [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
411 PPP3CB [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
412 PPP3CB [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
413 PPP3CB [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
414 PPP3CC [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
415 PPP3CC [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
416 PPP3CC [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
417 PPP3CC [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
418 PPP3CC [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
419 PPP3R1 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
420 PPP3R1 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
421 PPP3R1 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
422 PPP3R1 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
423 PPP3R1 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
424 PPP3R2 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
425 PPP3R2 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
426 PPP3R2 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
427 PPP3R2 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
428 PPP3R2 [24] MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
429 PRKCE [10] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Tight junction, Fc gamma R-mediated phagocytosis, Inflammatory mediator regulation of TRP channels, Type II diabetes mellitus, Insulin resistance, Shigellosis, MicroRNAs in cancer D09671 Sotrastaurin [1] 97
430 MAP2K1 [77] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
431 MAP2K1 [77] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
432 MAP2K1 [77] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
433 MAP2K1 [77] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
434 MAP2K2 [66] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
435 MAP2K2 [66] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
436 MAP2K2 [66] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
437 MAP2K2 [66] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
438 RAF1 [69] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06272 Sorafenib [2] 34, 86
439 RAF1 [69] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib [2] 34, 86
440 ROCK1 [18] cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer D07941 Fasudil [4] 2, 5, 7, 51
441 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
442 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
443 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
444 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
445 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
446 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
447 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
448 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
449 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
450 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
451 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
452 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
453 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
454 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
455 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
456 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
457 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
458 CACNA1C [26] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
459 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
460 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
461 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
462 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
463 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
464 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
465 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
466 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
467 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
468 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
469 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
470 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
471 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
472 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
473 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
474 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
475 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
476 CACNA1D [25] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
477 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
478 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
479 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
480 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
481 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
482 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
483 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
484 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
485 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
486 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
487 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
488 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
489 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
490 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
491 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
492 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
493 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
494 CACNA1F [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
495 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
496 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
497 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
498 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
499 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
500 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
501 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
502 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
503 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
504 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
505 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
506 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
507 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
508 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
509 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
510 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
511 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
512 CACNA1S [20] MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
513 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00302 Dipyridamole [6] 46, 49, 51, 66, 96, 224
514 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
515 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
516 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil [7] 6, 51, 75, 84, 86, 113, 210
517 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02229 Sildenafil [17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
518 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02731 Vardenafil [3] 13, 86, 299
519 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D03260 Vardenafil [3] 13, 86, 299
520 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil [17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
521 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08668 Vardenafil [3] 13, 86, 299
522 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D10027 Udenafil [2] 86, 210
523 ROCK2 [19] cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D07941 Fasudil [4] 2, 5, 7, 51
524 ROCK2 [19] cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D11815 Belumosudil [1] 51